New First-Line Treatment Option for NSCLC: Nivolumab + Ipilimumab + Chemotherapy
First-line treatment with nivolumab in combination with ipilimumab and chemotherapy provided durable survival compared with chemotherapy alone in patients with NSCLC.
Sucharita Mistry, PhD
Sucharita Mistry is an Oncology Writer for the Haymarket oncology brands. She is a prolific medical writer with a vast background in hematology and medical oncology research. She had previously served as a faculty at the Icahn School of Medicine at Mount Sinai, where her research was focused on developing novel therapeutic strategies for prostate and breast cancer. In a subsequent role, she was a Biomedical Science Writer in the Division of Hematology-Medical Oncology at Weill Cornell Medicine. Sucharita holds a Master’s degree in Molecular Biology from Fairleigh Dickinson University and a Ph.D. in Cancer Biology from the State University of New York, Health Science Center at Brooklyn.
